Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity
出版年份 2012 全文链接
标题
Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity
作者
关键词
-
出版物
PLoS One
Volume 7, Issue 6, Pages e38744
出版商
Public Library of Science (PLoS)
发表日期
2012-06-23
DOI
10.1371/journal.pone.0038744
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging
- (2011) Águeda González-Rodríguez et al. AGING CELL
- Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice
- (2011) J. Shirakawa et al. DIABETES
- The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus
- (2011) T. Forst et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2011) R. Gomis et al. DIABETES OBESITY & METABOLISM
- Linagliptin
- (2011) Lesley J. Scott DRUGS
- Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications
- (2010) Michael A. Nauck AMERICAN JOURNAL OF MEDICINE
- Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats
- (2010) Bárbara Maiztegui et al. CLINICAL SCIENCE
- Insulin Resistance in Nonalcoholic Fatty Liver Disease
- (2010) E. Bugianesi et al. CURRENT PHARMACEUTICAL DESIGN
- Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
- (2010) A. J. Scheen DIABETES OBESITY & METABOLISM
- Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2010) M.-R. Taskinen et al. DIABETES OBESITY & METABOLISM
- Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
- (2010) S. Del Prato et al. DIABETES OBESITY & METABOLISM
- The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans
- (2010) S. Blech et al. DRUG METABOLISM AND DISPOSITION
- Liver-specific suppressor of cytokine signaling-3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity1
- (2010) Nirupa Sachithanandan et al. HEPATOLOGY
- Myeloid Cell-Restricted Insulin Receptor Deficiency Protects Against Obesity-Induced Inflammation and Systemic Insulin Resistance
- (2010) Jan Mauer et al. PLoS Genetics
- Thiazolidinediones and the liver in humans
- (2009) Hannele Yki-Järvinen CURRENT OPINION IN LIPIDOLOGY
- Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients
- (2009) T. Heise et al. DIABETES OBESITY & METABOLISM
- Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
- (2009) Carolyn F Deacon et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans
- (2009) Holger Fuchs et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors
- (2008) L. Thomas et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
- (2008) W. Kim et al. PHARMACOLOGICAL REVIEWS
- Measurements of Islet Function and Glucose Metabolism with the Dipeptidyl Peptidase 4 Inhibitor Vildagliptin in Patients with Type 2 Diabetes
- (2007) Koichiro Azuma et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now